$AIM Up 38% Premarket! 🚀 🔹 AIM ImmunoTech is an immuno-pharma company developing Ampligen for cancers, viral diseases, and immune-disorder indications 🔹 Rece

$AIM Up 38% Premarket! 🚀 🔹 AIM ImmunoTech is an immuno-pharma company developing Ampligen for cancers, viral diseases, and immune-disorder indications 🔹 Recent catalyst: virtual KOL segment spotlighted Ampligen data in late-stage pancreatic cancer 👀 🔹 DURIPANC update expected mid-2026, with enr…